Summary by Moomoo AI
C4 Therapeutics (C4T) has reported significant developments in its collaboration agreements with Roche, Biogen, and Calico, focusing on the research, development, and commercialization of novel treatments using the company's proprietary TORPEDO platform. Under the amended Roche Agreement, C4T received an upfront payment of $40 million and may receive increased royalties and reimbursement for commercialization costs if it opts into co-development rights. Roche has the option to license and commercialize products for two targets, with potential milestone payments to C4T up to $273 million per target and sales-based milestone payments up to $150 million per target. The Biogen Agreement, which concluded its research term as of March 31, 2024, involved collaboration on treatments for neurological conditions. C4T received a $45 million upfront payment and is eligible for up to...Show More